Retinitis Pigmentosa

View All

Pharma News for Actinium, Santhera, Gilead, Seres, BMS, Boehringer
Actinium Announces SIERRA Trial Results; Santhera Seeks FDA Review for Vamorolone; Seres Announces BLA Submission for SER-109; BMS Announces Results of COMMANDS Trial; Boehringer’s PDE4B Moves Late-stage Clinical Testing; FDA Rejects Gilead’s Hepcludex; Approval to J&J’s BCMAxCD3 Bispecific Antibody for Multiple Myeloma; Syncona to Acquire AGTC

Actinium Announces Positive Top-line Results from Pivotal Phase III SIERRA Trial of Iomab-B Actinium Pharma is on track to submit its targeted radiotherapy for AML patients requiring a bone marrow transplant in the United States, boosted by top-line data from a pivotal trial. The SIERRA trial of Iomab-B, an anti...

Find More

Pharma News Merck, AstraZeneca, and GSK
Merck’s Sotatercept Trial Result; PARP Rivals Closing in on AstraZeneca and Merck’s Lynparza; FDA Clears GSK’s Boostrix for Pertussis; Fast Track Designation to Nanoscope Therapeutics’s MCO-010; FDA Awards Fast Track Designation to Eftilagimod Alpha Plus Pembrolizumab; Solid Biosciences to Acquire AavantiBio

Merck’s Sotatercept Clears Phase III Trial Merck’s USD 11.5 billion acquisition of Acceleron last year was based on the promise of pulmonary arterial hypertension (PAH) candidate sotatercept, which has recently met the mark in a much-anticipated phase III trial. The STELLAR trial found that adding the activin re...

Find More

Retinitis pigmentosa
What is driving Retinitis pigmentosa market forward?

DelveInsight estimates an increase in Retinitis Pigmentosa Market Size during the study period 2017–2030, from USD 237.27 million, as reported in 2017 in the 7MM. The increase in the Retinitis pigmentosa market size, as estimated by DelveInsight, is a direct consequence of the expected launch of potential therap...

Find More

Retinitis Pigmentosa
Retinitis Pigmentosa: A complex disease, and the increasing gap between prevalence and diagnosed prevalence

DelveInsight’s Retinitis Pigmentosa Epidemiology forecast analysis revealed that the prevalent population of the disease is expected to increase during the study period 2017-30. Retinitis Pigmentosa Defects and Diagnosis A group of inherited genetic retinal diseases – Retinitis pigmentosa – leads to progressi...

Find More

BioGen
Notizia

UK based company conducting clinical trials on World's First Universal Flu Vaccine UK based company Vaccitech is currently conducting a clinical trial on a prospective drug that could serve as a universal flu vaccine in the world. Currently, there is no vaccine in the market that can be used for multiple flu probl...

Find More

Retinal Degeneration
Retinal Degeneration : The Current Pipeline Scenario

Retinal Degeneration is the deterioration of the retina caused by the progressive and eventual death of the retinal cells. It is the damage to photoreceptor cells of the retina which malfunctions and distorts the received image. This is often a progressive disease in which the patient will suffer a continuous declin...

Find More